Get notified when TEVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTeva Pharmaceutical holds routine annual meeting, elects director and approves auditor
Filed May 28, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
low
Shareholders elected Dr. Sol J. Barer to the board through 2029, with 628M votes in favor versus 246M against.
Item 5.07 verify on EDGAR → -
low
Executive compensation approved on advisory basis with 796M votes in favor, indicating shareholder support for management pay practices.
Item 5.07 verify on EDGAR → -
low
PwC reappointed as independent auditor through 2027 annual meeting with 881M votes in favor, representing strong shareholder backing.
Item 5.07 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade TEVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · May 29, 2026 12:05 AM